CD79A and diffuse large B-cell lymphoma: Two new MoAbs approved for treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) are the anti-CD19 tafasitamab, and the anti-CD79a conjugated with monomethyl auristatin E polatuzumab vedotin [158,159].